2020 has been a year where no part of society has been left untouched due to COVID-19. This also goes for Novo Nordisk Pharmatech, who for better and worse, has been able to navigate this challenging business environment. Read or download the annual report here. In March, the company reduced its operation to a minimum due to lock-down, while at the same time experiencing a surge in demand for Insulin and Quats. The increased insulin demand was driven partly by stockpiling in the biopharmaceutical industry and partly by an increased activity due to COVID-19 driven activities. The Quats product group ... read more